Sandhya Mehta

home / authors / sandhya-mehta

Articles

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

Sandhya Mehta;Kristin M. Zimmerman Savill;Peng Wang;Prathamesh Pathak;Clara Lam;Jackie Kwong;Bruce Feinberg

65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

Sandhya Mehta;Anupama Vasudevan;John Li;Dawn Brenneman;Jackie Kwong

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Published: January 24th 2025 | Updated: February 6th 2025

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

Published: September 13th 2024 | Updated: November 25th 2024

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Published: August 9th 2024 | Updated: August 14th 2024

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Published: June 2nd 2024 | Updated: June 3rd 2024

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

A 49-Year-Old Woman Notes the Onset of a Painful Reddish-Blue Discoloration Under One Fingernail

Published: June 26th 2012 | Updated: April 3rd 2025

A 49-Year-Old Woman Notes the Onset of a Painful Reddish-Blue Discoloration Under One Fingernail

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.